China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Hunan Xiangzhong Pharmaceutical, received approval from the Chinese drug administration to produce and market levetiracetam oral solution, according to a Shanghai Stock Exchange disclosure on Tuesday.
The National Medical Products Administration handed down a drug registration certificate to the pharmaceutical company.
The drug is an adjunctive treatment for partial seizures in adults, children and infants over one month of age with epilepsy, the disclosure said.
The company's shares rose 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.